Gilead notches another Phase 3 win for Trodelvy in triple-negative breast cancer
Gilead’s Trodelvy has passed another late-stage test in certain patients with metastatic triple-negative breast cancer (TNBC) — a win the company says could pave the way for the drug to become a foundational treatment in the ...
Gilead’s Trodelvy has passed another late-stage test in certain patients with metastatic triple-negative breast cancer (TNBC) — a win the company says could pave the way for the drug to become a foundational treatment in the ...
